1. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. (December 2016) Authors: Gainor, J.; Dardaei, L.; Yoda, S.; Friboulet, L.; Leischler, I.; Katayama, R.; Dagogo-Jack, I.; Gadgeel, S.; Schultz, K.; Singh, M.; Chin, E.; Parks, M.; Lee, D.; DiCecca, R.H.; Lockerman, E.; Huynh, T.; Logan, J.; Benes, C.H.; Engelman, J.A.; Shaw, A. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. NAMPT inhibition is a novel synthetic lethal therapeutic approach exploiting nuclear–mitochondrial crosstalk in ERCC1-deficient populations. (December 2016) Authors: Touat, M.; Olaussen, K.; Sourisseau, T.; Friboulet, L.; Dorvault, N.; Enot, D.; Bigot, L.; Pontoizeau, C.; Mardakheh, F.; Thompson, A.; Bouillaud, F.; Ricchetti, M.; Ottolenghi, C.; Pierron, G.; Sarasin, A.; Lombès, A.; Ashworth, A.; Lord, C.; Soria, J.C.; Postel-Vinay, S. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation. (October 2022) Authors: Fujino, T.; Nguyen, L.; Yoda, S.; Yu, M.; Mizuta, H.; Bigot, L.; Nobre, C.; Tangpeerachaikul, A.; Pelish, H.E.; Friboulet, L.; Lee, J.; Cho, B.; Hata, A.N. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗